Back to Authors

O'Brien, Michael

Mayo Clinic

Department of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA.

Citations 1

Rebound Phenomenon After Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease 2019 (COVID-19) in High-Risk Persons
Tulledge‐Scheitel, Sidna M. , Pike, Marsha L., O’Brien, M D , Razonable, Raymund R. , Shah, Aditya , Challener, Douglas W. , Tulledge-Scheitel, Sidna M, O'Brien, Michael, Razonable, Raymund R , Shah, Aditya S , Ranganath, Nischal , O’Horo, John C. , O’Brien, Michael

Clinical Infectious Diseases | June 14, 2022 | Volume: 76 | Issue: 3 | Pages: e537-e539

10.1093/cid/ciac481 Get It

Abstract In a cohort of 483 high-risk patients treated with nirmatrelvir/ritonavir for COVID-19, 2 patients (0.4%) required hospitalization by day 30. Four patients (0.8%) experienced rebound of symptoms, which were generally mild, at a median of 9 days after treatment, and all resolved without additional COVID-19–directed therapy.